Bicifadine

Routes of
administrationOral

ATC code

• none

Legal status

• US: Unscheduled

Elimination half-life1.6 hours

Bicifadine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	US: Unscheduled
Pharmacokinetic data
Elimination half-life	1.6 hours
Excretion	renal
Identifiers
IUPAC name 1-(4-Methylphenyl)-3-azabicyclo[3.1.0]hexane
CAS Number	71195-57-8 Y
PubChem CID	47953
ChemSpider	9889978 Y
UNII	B0SV3N7J3H
ChEMBL	ChEMBL511099 N
CompTox Dashboard (EPA)	DTXSID20867995
ECHA InfoCard	100.124.957
Chemical and physical data
Formula	C12H15N
Molar mass	173.259 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cc(ccc1C)[C@]32CNC[C@@H]2C3
InChI InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3/t11-,12+/m0/s1 Y Key:OFYVIGTWSQPCLF-NWDGAFQWSA-N Y
NY (what is this?)  (verify)

Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.^[1][2][3]

In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a phase III clinical trial for chronic low back pain.^[4][5][6] XTL ran a phase IIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008;l.^[7] XTL terminated the agreement in 2010.^[8] In 2010, Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.^[9]

Bicifadine has a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.^[10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."^[11]